GEHC · Ge Healthcare Technologies Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5.13B | - | $5.14B | $5.01B | $4.78B | - | $4.86B | $4.84B | $4.65B | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | $1.98B | - | $1.99B | $1.99B | $2.01B | - | $2.03B | $2.00B | $1.90B | - |
| R&D | $345.00M | - | $292.00M | $302.00M | $344.00M | - | $316.00M | $327.00M | $324.00M | - |
| SG&A | $1.12B | - | $1.04B | $1.03B | $1.04B | - | $1.03B | $1.07B | $1.04B | - |
| Total Operating Expenses | $1.46B | - | $1.34B | $1.33B | $1.38B | - | $1.35B | $1.40B | $1.36B | - |
| D&A | $78.00M | - | - | - | $66.00M | - | - | - | $68.00M | - |
| Operating Income | $515.00M | - | $653.00M | $654.00M | $629.00M | - | $676.00M | $608.00M | $540.00M | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | $94.00M | - | $179.00M | $113.00M | $104.00M | - | $168.00M | $143.00M | $124.00M | - |
| Net Income | $389.00M | - | $446.00M | $486.00M | $564.00M | - | $470.00M | $428.00M | $374.00M | - |
| EPS - Basic | $0.85 | - | $0.98 | $1.06 | $1.23 | - | $1.03 | $0.94 | $0.82 | - |
| EPS - Diluted | $0.85 | - | $0.98 | $1.06 | $1.23 | - | $1.02 | $0.93 | $0.81 | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $2.26B | $4.49B | $4.00B | $3.74B | $2.45B | $2.87B | $3.55B | $2.00B | $2.55B | $2.49B |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | $2.35B | $2.23B | $2.30B | $2.28B | $2.16B | $1.94B | $2.12B | $2.02B | $1.99B | $1.96B |
| Accounts Payable | $3.41B | $3.25B | $2.99B | $2.98B | $3.15B | $3.02B | $2.91B | $2.82B | $2.93B | $2.95B |
| Current Assets | $10.43B | $12.50B | $11.89B | $11.31B | $9.73B | $9.90B | $10.64B | $8.81B | $9.37B | $9.41B |
| Total Assets | $37.13B | $36.91B | $36.13B | $35.50B | $33.59B | $33.09B | $33.85B | $31.85B | $32.21B | $32.45B |
| Current Liabilities | $8.53B | $9.11B | $10.07B | $9.75B | $9.97B | $9.55B | $8.67B | $8.32B | $8.86B | $8.98B |
| Long-term Debt | $10.13B | $9.49B | $8.28B | $8.27B | $6.76B | $7.45B | $9.31B | $8.23B | $8.25B | $8.44B |
| Total Liabilities | $26.23B | $26.31B | $25.91B | $25.55B | $24.17B | $24.44B | $25.34B | $23.86B | $24.61B | $25.14B |
| Stockholders' Equity | $10.67B | $10.38B | $9.99B | $9.71B | $9.19B | $8.45B | $8.32B | $7.80B | $7.41B | $7.13B |
| Retained Earnings | $5.65B | $5.28B | $4.71B | $4.29B | $3.81B | $3.26B | $2.56B | $2.10B | $1.69B | $1.33B |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $290.00M | - | - | - | $250.00M | - | - | - | $419.00M | - |
| Investing Cash Flow | ($2.50B) | - | - | - | ($407.00M) | - | - | - | ($188.00M) | - |
| Financing Cash Flow | $21.00M | - | - | - | ($286.00M) | - | - | - | ($153.00M) | - |
| CapEx | $178.00M | - | - | - | $152.00M | - | - | - | $145.00M | - |
| Free Cash Flow | $112.00M | - | - | - | $98.00M | - | - | - | $274.00M | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 38.5% | - | 38.7% | 39.6% | 42.1% | - | 41.7% | 41.4% | 40.9% | - |
| Operating margin | 10.0% | - | 12.7% | 13.1% | 13.2% | - | 13.9% | 12.6% | 11.6% | - |
| EBITDA margin | 11.6% | - | - | - | 14.5% | - | - | - | 13.1% | - |
| Net margin | 7.6% | - | 8.7% | 9.7% | 11.8% | - | 9.7% | 8.8% | 8.0% | - |
| Free cash flow margin | 2.2% | - | - | - | 2.1% | - | - | - | 5.9% | - |
| FCF / Net income | 0.29 | - | - | - | 0.17 | - | - | - | 0.73 | - |
| R&D / Revenue | 6.7% | - | 5.7% | 6.0% | 7.2% | - | 6.5% | 6.8% | 7.0% | - |
| SG&A / Revenue | 21.8% | - | 20.3% | 20.6% | 21.8% | - | 21.3% | 22.1% | 22.3% | - |
| Effective tax rate | 19.5% | - | 28.6% | 18.9% | 15.6% | - | 26.3% | 25.0% | 24.9% | - |
| Return on assets | 1.0% | - | 1.2% | 1.4% | 1.7% | - | 1.4% | 1.3% | 1.2% | - |
| Return on equity | 3.6% | - | 4.5% | 5.0% | 6.1% | - | 5.7% | 5.5% | 5.0% | - |
| Return on invested capital | 2.0% | - | 2.6% | 3.0% | 3.3% | - | 2.8% | 2.8% | 2.6% | - |
| Liquidity | ||||||||||
| Current ratio | 1.22 | 1.37 | 1.18 | 1.16 | 0.98 | 1.04 | 1.23 | 1.06 | 1.06 | 1.05 |
| Quick ratio | 0.95 | 1.13 | 0.95 | 0.93 | 0.76 | 0.83 | 0.98 | 0.82 | 0.83 | 0.83 |
| Cash ratio | 0.27 | 0.49 | 0.40 | 0.38 | 0.25 | 0.30 | 0.41 | 0.24 | 0.29 | 0.28 |
| Leverage | ||||||||||
| Debt / Equity | 0.95 | 0.91 | 0.83 | 0.85 | 0.74 | 0.88 | 1.12 | 1.06 | 1.11 | 1.18 |
| Debt / Assets | 0.27 | 0.26 | 0.23 | 0.23 | 0.20 | 0.23 | 0.27 | 0.26 | 0.26 | 0.26 |
| Debt / EBITDA | 17.08 | - | - | - | 9.72 | - | - | - | 13.56 | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 3.48 | 3.56 | 3.62 | 3.66 | 3.66 | 3.92 | 4.07 | 4.08 | 4.35 | 4.55 |
| Liabilities / Assets | 0.71 | 0.71 | 0.72 | 0.72 | 0.72 | 0.74 | 0.75 | 0.75 | 0.76 | 0.77 |
| Efficiency | ||||||||||
| Asset turnover | 0.14 | - | 0.14 | 0.14 | 0.14 | - | 0.14 | 0.15 | 0.14 | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | 83.7x | - | 76.6x | 69.9x | 65.6x | - | 92.0x | 83.8x | 112.2x | - |
| P / B | 3.0x | - | 3.4x | 3.5x | 4.0x | - | 5.2x | 4.6x | 5.6x | - |
| P / S | 6.3x | - | 6.7x | 6.8x | 7.8x | - | 8.9x | 7.4x | 9.0x | - |
| EV / EBITDA | 68.1x | - | - | - | 59.5x | - | - | - | 78.0x | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 7.4% | - | 5.8% | 3.5% | 2.7% | - | 0.9% | 0.5% | -1.2% | - |
| Revenue CAGR (3y) | 2.9% | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | -1.7% | - | -1.8% | -0.8% | 5.8% | - | 4.7% | 3.2% | 13.3% | - |
| Operating income growth (YoY) | -18.1% | - | -3.4% | 7.6% | 16.5% | - | 9.6% | 6.7% | -3.4% | - |
| Net income growth (YoY) | -31.0% | - | -5.1% | 13.6% | 50.8% | - | 25.3% | 2.4% | -3.9% | - |
| EPS growth (YoY) | -30.9% | - | -3.9% | 14.0% | 51.9% | - | 24.4% | 2.2% | 97.6% | - |
| EPS CAGR (3y) | 27.5% | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | 14.3% | - | - | - | -64.2% | - | - | - | -25.5% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 16.1% | 22.9% | 20.2% | 24.5% | 24.0% | 18.4% | 16.6% | 9.8% | -20.8% | - |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$17.15B totalImaging Segment$9.24B · 53.9%
PDx Segment$2.90B · 16.9%
AVSSegment$2.75B · 16.0%
PCSSegment$2.26B · 13.2%
Product / service
$20.63B totalProduct$13.66B · 66.2%
Service$6.96B · 33.8%
Geographic
$20.63B totalOther Countries$9.43B · 45.7%
US$9.17B · 44.4%
CN$2.03B · 9.8%
Peer comparison
Same SIC group: X-Ray Apparatus & Tubes & Related Irradiation Apparatus
Comparing GE HealthCare Technologies Inc. against the 4 most active filers in the same SIC group.
Dividends
$0.14/share trailing 12 months · +7.7% YoY
| Ex-date | Per share |
|---|---|
| Apr 2, 2026 | $0.0350 |
| Jan 9, 2026 | $0.0350 |
| Oct 24, 2025 | $0.0350 |
| Jul 25, 2025 | $0.0350 |
| Apr 25, 2025 | $0.0350 |
| Jan 14, 2025 | $0.0350 |
| Oct 18, 2024 | $0.0300 |
| Jul 19, 2024 | $0.0300 |
| Apr 18, 2024 | $0.0300 |
| Jan 12, 2024 | $0.0300 |
| Oct 19, 2023 | $0.0300 |
| Jul 20, 2023 | $0.0300 |
| May 22, 2023 | $0.0300 |